{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:52:35Z","timestamp":1791899555014,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["RO4949097"],"award-info":[{"award-number":["RO4949097"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.clbc.2021.10.013","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T14:25:01Z","timestamp":1635431101000},"page":"103-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["A Phase Ib Dose Escalation Trial of RO4929097 (a \u03b3-secretase inhibitor) in Combination with Exemestane in Patients with ER\u00a0+\u00a0Metastatic Breast Cancer (MBC)"],"prefix":"10.1016","volume":"22","author":[{"given":"Julie A.","family":"Means-Powell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid A.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roohi","family":"Ismail-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3894-9206","authenticated-orcid":false,"given":"Luis","family":"Del Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Tonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6855-1322","authenticated-orcid":false,"given":"Vandana G.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda S.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Lush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samarpan","family":"Majumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-7287","authenticated-orcid":false,"given":"Lucio","family":"Miele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clbc.2021.10.013_bib0001","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrclinonc.2015.61","article-title":"Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update","volume":"12","author":"Takebe","year":"2015","journal-title":"Nature Rev Clin Oncol"},{"key":"10.1016\/j.clbc.2021.10.013_bib0002","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-3-030-55031-8_13","article-title":"Notch pathway: a journey from notching phenotypes to cancer immunotherapy","volume":"1287","author":"Monticone","year":"2021","journal-title":"Advances exp med biol"},{"key":"10.1016\/j.clbc.2021.10.013_bib0003","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41573-020-00091-3","article-title":"Targeting notch in oncology: the path forward","volume":"20","author":"Majumder","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clbc.2021.10.013_bib0004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2013.08.027","article-title":"Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells","volume":"341","author":"Espinoza","year":"2013","journal-title":"Cancer letters"},{"key":"10.1016\/j.clbc.2021.10.013_bib0005","first-page":"1249","article-title":"Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition","volume":"6","author":"Espinoza","year":"2013","journal-title":"OncoTargets therapy"},{"key":"10.1016\/j.clbc.2021.10.013_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2013.02.003","article-title":"Notch inhibitors for cancer treatment","author":"Espinoza","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clbc.2021.10.013_bib0007","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nature03659","article-title":"Notch\/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells","volume":"435","author":"van Es","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2021.10.013_bib0008","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/leu.2009.75","article-title":"NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia","volume":"23","author":"Real","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clbc.2021.10.013_bib0009","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1038\/oncsis.2013.26","article-title":"Crosstalk between PKCalpha and Notch-4 in endocrine-resistant breast cancer cells","volume":"2","author":"Yun","year":"2013","journal-title":"Oncogenesis"},{"key":"10.1016\/j.clbc.2021.10.013_bib0010","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1158\/0008-5472.CAN-07-5744","article-title":"Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches","volume":"68","author":"Rizzo","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2021.10.013_bib0011","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/onc.2009.323","article-title":"Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells","volume":"29","author":"Hao","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.clbc.2021.10.013_bib0012","doi-asserted-by":"crossref","first-page":"e71440","DOI":"10.1371\/journal.pone.0071440","article-title":"17beta-estradiol enhances signalling mediated by VEGF-A-delta-like ligand 4-notch1 axis in human endothelial cells","volume":"8","author":"Caliceti","year":"2013","journal-title":"PloS one"},{"issue":"8","key":"10.1016\/j.clbc.2021.10.013_bib0013","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1073\/pnas.1106509108","article-title":"Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch","volume":"109","author":"Haughian","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.clbc.2021.10.013_bib0014","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2018.04.023","article-title":"Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines","volume":"428","author":"Gelsomino","year":"2018","journal-title":"Cancer letters"},{"key":"10.1016\/j.clbc.2021.10.013_bib0015","series-title":"Abstracts of the 37th San Antonio Breast Cancer Symposium","article-title":"Identification of a notch-driven breast cancer stem cell gene signature for anti-notch therapy in an ER+ presurgical window model","author":"Albain","year":"2014"},{"key":"10.1016\/j.clbc.2021.10.013_bib0016","first-page":"230","article-title":"Correlation of Notch1, pAKT and nuclear NF-kappaB expression in triple negative breast cancer","volume":"3","author":"Zhu","year":"2013","journal-title":"Am J cancer res"},{"key":"10.1016\/j.clbc.2021.10.013_bib0017","doi-asserted-by":"crossref","first-page":"21666","DOI":"10.1074\/jbc.271.35.21666","article-title":"Protein kinase C isozymes differentially regulate promoters containing PEA-3\/12-O-tetradecanoylphorbol-13-acetate response element motifs","volume":"271","author":"Reifel-Miller","year":"1996","journal-title":"J biol chem"},{"key":"10.1016\/j.clbc.2021.10.013_bib0018","first-page":"3853","article-title":"Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation","volume":"30","author":"Grudzien","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clbc.2021.10.013_bib0019","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2011.36.8282","article-title":"Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors","volume":"30","author":"Tolcher","year":"2012","journal-title":"J clin oncol"},{"key":"10.1016\/j.clbc.2021.10.013_bib0020","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1158\/1078-0432.CCR-11-2684","article-title":"Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the gamma-secretase inhibitor RO4929097","volume":"18","author":"Wu","year":"2012","journal-title":"Clin cancer res"},{"key":"10.1016\/j.clbc.2021.10.013_bib0021","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s10637-013-0001-5","article-title":"A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors","volume":"31","author":"Diaz-Padilla","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clbc.2021.10.013_bib0022","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.1158\/0008-5472.CAN-09-1843","article-title":"Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties","volume":"69","author":"Luistro","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2021.10.013_bib0023","doi-asserted-by":"crossref","first-page":"950","DOI":"10.15252\/emmm.201607265","article-title":"gamma-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct","volume":"9","author":"Ran","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.clbc.2021.10.013_bib0024","unstructured":"FDA. Aromasin package insert 1999."},{"key":"10.1016\/j.clbc.2021.10.013_bib0025","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.bjc.6600923","article-title":"Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure","volume":"88","author":"Tonetti","year":"2003","journal-title":"British J Cancer"},{"key":"10.1016\/j.clbc.2021.10.013_bib0026","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1158\/0008-5472.CAN-09-1681","article-title":"Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor","volume":"70","author":"Harrison","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2021.10.013_bib0027","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.celrep.2015.08.050","article-title":"Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity","volume":"12","author":"Simoes","year":"2015","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.clbc.2021.10.013_bib0028","first-page":"77","article-title":"Breast cancer stem cells","volume":"6","author":"Crabtree","year":"2018","journal-title":"Biomed"},{"key":"10.1016\/j.clbc.2021.10.013_bib0029","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1158\/0008-5472.CAN-10-1559","article-title":"Breast cancer stem cells: something out of notching?","volume":"70","author":"Harrison","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2021.10.013_bib0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000508675","article-title":"Endocrine-resistant breast cancer: mechanisms and treatment","volume":"15","author":"Hartkopf","year":"2020","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.clbc.2021.10.013_bib0031","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/nm.3615","article-title":"Inhibition of Notch signaling promotes browning of white adipose tissue and ameliorates obesity","volume":"20","author":"Bi","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.clbc.2021.10.013_bib0032","doi-asserted-by":"crossref","first-page":"18814","DOI":"10.1073\/pnas.1104943108","article-title":"Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms","volume":"108","author":"Landor","year":"2011","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"10.1016\/j.clbc.2021.10.013_bib0033","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature13495","article-title":"Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia","volume":"513","author":"Dail","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2021.10.013_bib0034","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cellsig.2013.09.021","article-title":"New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of gamma-secretase inhibitor resistant T-cell acute lymphoblastic leukemia","volume":"26","author":"Hales","year":"2014","journal-title":"Cellular signalling"},{"key":"10.1016\/j.clbc.2021.10.013_bib0035","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-15-1640-T","article-title":"Treatment of triple-negative breast cancer with torc1\/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population","volume":"76","author":"Bhola","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2021.10.013_bib0036","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/bjc.2011.321","article-title":"Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence","volume":"105","author":"Pandya","year":"2011","journal-title":"Br.J Cancer"},{"key":"10.1016\/j.clbc.2021.10.013_bib0037","doi-asserted-by":"crossref","first-page":"R62","DOI":"10.1186\/bcr3675","article-title":"Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells","volume":"16","author":"Lombardo","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2021.10.013_bib0038","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2045-824X-4-7","article-title":"Notch signals in the endothelium and cancer \"stem-like\" cells: opportunities for cancer therapy","volume":"4","author":"Gu","year":"2012","journal-title":"Vasc.Cell"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820921003049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820921003049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:56:03Z","timestamp":1778817363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820921003049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1526820921003049"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2021.10.013","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase Ib Dose Escalation Trial of RO4929097 (a \u03b3-secretase inhibitor) in Combination with Exemestane in Patients with ER\u00a0+\u00a0Metastatic Breast Cancer (MBC)","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2021.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}